REFERENCES
  1. Noris P, Spedini P, Belletti S, Magrini U, Balduini CL. Thrombocytopenia, giant platelets, and leukocyte inclusion bodies (May-Hegglin anomaly): clinical and laboratory findings. Am J Med. 1998;104(4):355-360.
  2. Althaus K, Greinacher A. MYH9-related platelet disorders. Semin Thromb Hemost. 2009;35(2):189-203.
  3. May R. Leukocyteneinschlusse. Deutsch Arch Klin Med.1909;96:1-6.
  4. Hegglin R. Gleichzeitige konstitutionelle veranderungen an neurtophilen und thrombocyten. Helv Med Acta. 1945;12:439-440.
  5. Heath KE, Campos-Barros A, Toren A, et al. Nonmuscle myosin heavy chain IIA mutations define a spectrum of autosomal dominant macrothrombocytopenias: May-Hegglin anomaly and Fechtner, Sebastian, Epstein, and Alport-like syndromes. Am J Hum Genet . 2001;69(5):1033-1045.
  6. Saito H, Kunishima S. Historical hematology: May-Hegglin anomaly. Am J Hematol. 2008;83(4):304-306.
  7. Kunishima S, Matsushita T, Shiratsuchi M, et al. Detection of unique neutrophil non-muscle myosin heavy chain-A localization by immunofluorescence analysis in MYH9 disorder presented with macrothrombocytopenia without leukocyte inclusions and deafness. Eur J Haematol. 2005(1);74:1-5.
  8. Kunishima S, Matsushita T, Kojima T, et al. Immunofluorescence analysis of neutrophil nonmuscle myosin heavy chain-A in MYH9 disorders: association of subcellular localization with MYH9 mutations. Lab Invest. 2003;83(1):115-122.
  9. Balduini CL, Savoia A, Seri M. Inherited thrombocytopenias frequently diagnosed in adults. J Thromb Haemost . 2013;11(6):1006-1019.
  10. Thakral B, Rojanapremsuk T, Saluja K, Eldibany M. Misdiagnosed MYH9 related inherited macrothrombocytopenia with an inadvertent splenectomy. Pathology. 2015;47(4):377-379.
  11. Rabbolini DJ, Chun Y, Latimer M, et al. Diagnosis and treatment of MYH9- RD in an Australasian cohort with thrombocytopenia. Platelets . 2018;29(8):793-800.
  12. Yoshinari M, Kunishima S, Miyabayashi S, Saito H, Tsuchiya S. A unique immunofluorescence method promotes accurate diagnosis in MYH9 disorders: a case report. J Pediatr Hematol Oncol.2004;26(9):579-583.
  13. Kodama R, Taketani T, Kunishima S, et al. A rare case of MYH9 disorders presenting with macrothrombocytopenia and deafness caused by MYH9-R702C mutation.Thromb Res. 2009;124(4):508-511.
  14. Wasano K, Matsunaga T, Ogawa K, Kunishima S. Late onset and high-frequency dominant hearing loss in a family with MYH9 disorder. Eur Arch Otorhinolaryngol.2016;273(11):3547-3552.
  15. Murayama S, Akiyama M, Namba H, Wada Y, Ida H, Kunishima S. Familial cases with MYH9 disorders caused by MYH9 S96L mutation.Pediatr Int.  2013;55(1):102-104.
  16. Pecci A, Klersy C, Gresele P, et al. MYH9 disease: a novel prognostic model to predict the clinical evolution of the disease based on genotype-phenotype correlations. Hum Mutat. 2014;35(2):236-247.
  17. Sirachainan N, Komwilaisak P, Kitamura K, Hongeng S, Sekine T, Kunishima S. The first two cases of MYH9 disorders in Thailand: an international collaborative study. Ann Hematol.2015;94(4):707-709.
  18. Arrondel C, Vodovar N, Knebelmann B, et al. Expression of the nonmuscle myosin heavy chain IIA in the human kidney and screening for MYH9 mutations in Epstein and Fechtner syndromes.J Am Soc Nephrol. 2002;13(1):65-74.
  19. Dong F, Li S, Pujol-Moix N, et al. Genotype-phenotype correlation in MYH9 thrombocytopenia.Br J Haematol. 2005;130(4):620-627.
  20. Sun XH, Wang ZY, Cao LJ, et al. Clinical features and gene analyses of six patients with MYH9 disease.Zhonghua Xue Ye Xue Za Zhi. 2012;33(7):552-555.
  21. Sun XH, Wang ZY, Yang HY, et al. Clinical, pathological, and genetic analysis of ten patients with MYH9 disease. Acta Haematol. 2013;129(2):106-113.
  22. Saposnik B, Binard S, Fenneteau O, et al. Mutation spectrum and genotype-phenotype correlations in a large French cohort of MYH9-Related Disorders. Mol Genet Genomic Med.2014;2(4):297-312.
  23. Pecci A, Verver EJ, Schlegel N, et al. Cochlear implantation is safe and effective in patients with MYH9-related disease. Orphanet J Rare Dis. 2014;9:100.